Total marrow irradiation-based, reduced-intensity conditioning regimen for elderly patients undergoing hematopoietic cell transplantation for hematological malignancies
Authors:
- Leonardo Javier ArcuriLALeonardo Javier Arcuri
- Mariana KerbauyMKMariana Kerbauy
- Lucila KerbauyLKLucila Kerbauy
- Juliana Dall’AGnol da RochaJRJuliana Dall’AGnol da Rocha
- Carolina PerroneCPCarolina Perrone
- Tarcila DatoguiaTDTarcila Datoguia
- Jade Zezzi Martins Do NascimentoJNJade Zezzi Martins Do Nascimento
- Morgani RodriguesMRMorgani Rodrigues
- Ana Carolina Pires de RezendeARAna Carolina Pires de Rezende
- Eduardo WeltmanEWEduardo Weltman
- Roberto SakurabaRSRoberto Sakuraba
- Andreza Alice Feitosa RibeiroARAndreza Alice Feitosa Ribeiro
Open Access
- 30 July 2026
- journal article
- research article
- Published by Springer Nature in Current Tissue Microenvironment Reports
- Vol. 7 (1) , 7
Abstract
Background: Elderly patients are increasingly being offered allogeneic hematopoietic cell transplantation (HCT), and several strategies have been developed to meet their needs. The objective of the current study was to report the feasibility of a reduced-intensity busulfan/fludarabine conditioning regimen with total marrow irradiation in older patients. Methods: This single-center study included 28 patients aged 60–77 years with a median follow-up of 34 months. Results: Overall survival at 2 years was 46%, relapse rate was 30%, and non-relapse mortality was 23%, yielding a progression-free survival of 46%. Rates of grades II-IV acute GVHD, III-IV acute GVHD, and chronic GVHD were 47%, 8%, and 19%, respectively. Only one patient did not achieve neutrophil engraftment. Three patients experienced sinusoidal obstruction syndrome, and all recovered. Causes of death included disease progression ( n = 10), infection ( n = 5, including one COVID-19 case), and acute myocardial infarction ( n = 1). Conclusion: Our results demonstrate the feasibility of an intensified, total marrow irradiation-based conditioning regimen in an elderly cohort, primarily comprising transplants from alternative donors for high-risk diseases. Non-relapse mortality was very low, given the patients’ profile, and compares favorably with others reports reduced-intensity regimen with total body irradiation in older patients. Future studies should compare it to the standard reduced-intensity and non-myeloablative regimens.Keywords
Funding Information
- Faculdade Israelita De Ciências Da Saúde Albert Einstein
This publication has 10 references indexed in Scilit:
- Allogeneic hematopoietic stem cell transplantation in elderly patients (age over 70 years) with high grade myelodysplasia or high risk acute myeloid leukemia.Journal of Clinical Oncology, 2025
- Hematopoietic cell transplantation for older acute myeloid leukemia patients in first complete remission: results of a randomized phase III studyHaematologica, 2024
- HCT in Elderly Patients2024
- Outcomes of Allogeneic HSCT in Elderly Patients (70 years old and above) -a Canadian ExperienceBlood, 2023
- How to improve the outcomes of elderly acute myeloid leukemia patients through allogeneic hematopoietic stem cell transplantationFrontiers in Immunology, 2023
- Current Status and Perspectives of Allogeneic Hematopoietic Stem Cell Transplantation in Elderly Patients with Acute Myeloid LeukemiaStem Cells Translational Medicine, 2022
- Targeted Marrow Irradiation Intensification of Reduced-Intensity Fludarabine/Busulfan Conditioning for Allogeneic Hematopoietic Stem Cell TransplantationTransplantation and Cellular Therapy, 2022
- Haematopoietic stem-cell transplantation in older adults: geriatric assessment, donor considerations, and optimisation of careThe Lancet Haematology, 2021
- Allotransplants for Patients 65 Years or Older with High-Risk Acute Myeloid LeukemiaTransplantation and Cellular Therapy, 2018
- Fludarabine and busulfan plus low-dose TBI as reduced intensity conditioning in older patients undergoing allogeneic hematopoietic cell transplant for myeloid malignanciesAnnals of Hematology, 2018